Market revenue in 2024 | USD 95.4 million |
Market revenue in 2030 | USD 163.4 million |
Growth rate | 9.2% (CAGR from 2025 to 2030) |
Largest segment | Biologics |
Fastest growing segment | PDE4 Inhibitors |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics |
Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 45.07% in 2024. Horizon Databook has segmented the Saudi Arabia atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2018 to 2030.
High unmet clinical needs, rise in disposable incomes, and increase in government expenditure on healthcare are creating opportunities for growth of the atopic dermatitis drugs market in Saudi Arabia. As per the Dermatology and Therapy Journal, in 2019, the prevalence of atopic dermatitis is highly variable in urban and rural regions of Saudi Arabia.
The desert-based geography of the country is resulting in the high rate of atopic dermatitis, as low humidity and high temperatures can increase dryness of the skin. Furthermore, as per Springer Journal, in 2019, the quality of life of patients is associated with severity of the disease.
For instance, 66.4% of patients had a moderate quality of life, while 30% had a low quality of life. This indicates higher prevalence of disease in moderate and low-income groups, creating a gap in the need for low-priced atopic dermatitis treatments.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia atopic dermatitis drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account